Dan Littman - Pfizer Director
| PFE Stock | EUR 24.50 0.09 0.37% |
Director
Dr. Dan R. Littman M.D., is the Director of Pfizer Inc.. He is also a member of the National Academy of the Sciences and the Institute of Medicine, and is a Fellow of the American Academy of Arts and Sciences and the American Academy of Microbiology since 2018.
| Age | 65 |
| Tenure | 6 years |
| Professional Marks | Ph.D |
| Phone | 212 733 2323 |
| Web | https://www.pfizer.com |
Pfizer Management Efficiency
The company has return on total asset (ROA) of 0.1287 % which means that it generated a profit of $0.1287 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.3622 %, meaning that it generated $0.3622 on every $100 dollars invested by stockholders. Pfizer's management efficiency ratios could be used to measure how well Pfizer manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Carolyn Bertozzi | Eli Lilly and | 49 | |
| Juan Luciano | Eli Lilly and | 54 | |
| Kathi Seifert | Eli Lilly and | 66 | |
| Marschall Runge | Eli Lilly and | 61 | |
| Roxanne Austin | AbbVie Inc | 57 | |
| Edward Rapp | AbbVie Inc | 60 | |
| Ralph Alvarez | Eli Lilly and | 61 | |
| Glenn Tilton | AbbVie Inc | 69 | |
| Frederick Waddell | AbbVie Inc | 64 | |
| Karen Horn | Eli Lilly and | 71 | |
| Robert Alpern | AbbVie Inc | 67 | |
| Jamere Jackson | Eli Lilly and | 47 | |
| Brett Hart | AbbVie Inc | 48 | |
| William Kaelin | Eli Lilly and | 58 | |
| Edward Liddy | AbbVie Inc | 72 | |
| Katherine Baicker | Eli Lilly and | 44 | |
| Rebecca Roberts | AbbVie Inc | 65 | |
| Michael Eskew | Eli Lilly and | 66 | |
| Erik Fyrwald | Eli Lilly and | 56 | |
| Raul Alvarez | Eli Lilly and | 61 | |
| Jackson Tai | Eli Lilly and | 66 | |
Management Performance
| Return On Equity | 0.36 | |||
| Return On Asset | 0.13 |
Pfizer Inc Leadership Team
Elected by the shareholders, the Pfizer's board of directors comprises two types of representatives: Pfizer inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Pfizer. The board's role is to monitor Pfizer's management team and ensure that shareholders' interests are well served. Pfizer's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Pfizer's outside directors are responsible for providing unbiased perspectives on the board's policies.
| John Young, Group President - Global Established Pharma Business | ||
| Jennifer Damico, Controller VP | ||
| Frank DAmelio, CFO, Executive Vice President - Business Operations | ||
| Douglas Lankler, Executive Vice President General Counsel | ||
| Dawn Rogers, Chief Human Resource Officer, Executive Vice President | ||
| Helen Hobbs, Independent Director | ||
| Shantanu Narayen, Director | ||
| James Smith, Director | ||
| Christopher CFA, VP Officer | ||
| Dennis Ausiello, Independent Director | ||
| Mikael Dolsten, President - Worldwide Research and Development | ||
| Frances Fergusson, Independent Director | ||
| Stephen Sanger, Independent Director | ||
| Lidia Fonseca, Executive Vice President CTO and Digital Officer | ||
| Wyllie Cornwell, Independent Director | ||
| Suzanne Johnson, Independent Director | ||
| David Denton, Chief VP | ||
| Alexander Mackenzie, Executive Vice President Chief Development Officer | ||
| DVM DVM, Chairman CEO | ||
| Geno Germano, Group President - Global Innovative Pharma Business | ||
| Laurie Olson, Executive Vice President - Strategy, Portfolio and Commercial Operations | ||
| Sally Susman, Executive Vice President - Corporate Affairs | ||
| Anthony Maddaluna, Executive Vice President and Presidentident - Pfizer Global Supply | ||
| Freda LewisHall, Executive Vice President Chief Medical Officer | ||
| Rady Johnson, Executive Vice President Chief Compliance and Risk Officer | ||
| Mikael MD, Dev Research | ||
| Dan Littman, Director | ||
| Ian Read, Chairman of the Board, CEO | ||
| James Kilts, Independent Director | ||
| Don Cornwell, Independent Director | ||
| Charles Hill, Executive Vice President - Worldwide Human Resources | ||
| Joseph Echevarria, Director | ||
| Albert Bourla, Group President - Vaccines, Oncology and Consumer Healthcare Business | ||
| Kirsten LundJurgensen, Executive Vice President and Presidentident - Pfizer Global Supply | ||
| Angela Hwang, Group President - Pfizer Essential Health | ||
| Scott Gottlieb, Director | ||
| Ronald Blaylock, Independent Director | ||
| Kathrin Jansen, Senior Vice President - Vaccine Research & Development | ||
| Michael Goettler, Group President - Pfizer Upjohn |
Pfizer Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Pfizer a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.36 | |||
| Return On Asset | 0.13 | |||
| Profit Margin | 0.31 % | |||
| Operating Margin | 0.39 % | |||
| Current Valuation | 276.06 B | |||
| Shares Outstanding | 5.62 B | |||
| Shares Owned By Insiders | 0.04 % | |||
| Shares Owned By Institutions | 71.00 % | |||
| Price To Earning | 16.17 X | |||
| Price To Book | 3.13 X |
Becoming a Better Investor with Macroaxis
Macroaxis puts the power of mathematics on your side. We analyze your portfolios and positions such as Pfizer Inc using complex mathematical models and algorithms, but make them easy to understand. There is no real person involved in your portfolio analysis. We perform a number of calculations to compute absolute and relative portfolio volatility, correlation between your assets, value at risk, expected return as well as over 100 different fundamental and technical indicators.Build Optimal Portfolios
Align your risk with return expectations
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Pfizer Inc. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. You can also try the FinTech Suite module to use AI to screen and filter profitable investment opportunities.
Complementary Tools for Pfizer Stock analysis
When running Pfizer's price analysis, check to measure Pfizer's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pfizer is operating at the current time. Most of Pfizer's value examination focuses on studying past and present price action to predict the probability of Pfizer's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Pfizer's price. Additionally, you may evaluate how the addition of Pfizer to your portfolios can decrease your overall portfolio volatility.
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes |